Zacks Investment Research
10 Oct 2025, 16:56 UTC · 49w ago
Verdict
Headline takes no side. We score BIIB −0.30 across four claims — moderately bearish.
−0.30moderately bearish
More negative than 72% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Biogen's core MS drugs (Tecfidera and Tysabri) and SMA treatment (Spinraza) are experiencing sales declines due to generic and biosimilar competition.
So whatLoss of exclusivity and increased competition in primary revenue drivers directly erode top-line growth and profit margins.
More negative than 98% of claims this week
A Tysabri biosimilar is expected to enter the United States market in the fourth quarter of 2025.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 91% of claims this week
Biogen's Leqembi for Alzheimer's disease has shown sequential sales improvements over the last four quarters and is viewed as a potential blockbuster.
So whatSuccessful scaling of a new blockbuster drug can offset losses from legacy products and drive long-term valuation.
More positive than 77% of claims this week
Biogen identifies Skyclarys and Zurzuvae as additional new drugs with strong demand trends to help revive long-term growth.
More positive than 50% of claims this week
Which stocks this story touches
More negative than 72% of ticker scores this week
The company is facing declining sales in its core MS and SMA drug portfolios due to generic and biosimilar competition.
More positive than 51% of ticker scores this week
Mentioned as providing competitive pressure to Biogen via its Zolgensma gene therapy.
More positive than 51% of ticker scores this week
Mentioned as providing competitive pressure to Biogen via its Evrysdi treatment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Market Watch
5h ago
Accesswire
7h ago
More positive than 76% of relationship scores this week
[mutual] Biogen's Spinraza competes with Evrysdi, developed by PTC Therapeutics and Roche.
+49.2%
Price is moving against the score
$223.16 vs $149.61 close before publication (Oct 9) · not market-adjusted
BIIB chart →
